Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 16/20 | 0.91 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.91 |
| ▸ | PDE4C | Q08493 | 16/20 | 0.91 |
| ▸ | PDE4D | Q08499 | 16/20 | 0.91 |
| ▸ | ADORA2A | P29274 | 12/20 | 0.91 |
| ▸ | ADORA2B | P29275 | 11/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4623455 | 0.95 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL515771 | 0.95 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| Ammonia Solution, Strong SCHEMBL10420651 | 0.94 | PDE4A (0.97) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL21381263 | 0.91 | ADORA2B (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL515564 | 0.91 | ADORA2A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL5006812 | 0.90 | ADORA2B (0.92) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL3842077 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL21381259 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL21381255 | 0.89 | ADORA2B (0.92) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL9430034 | 0.88 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10226467-B2 | Compounds for the treatment of myotonic dystrophy | UNIVERSITAT DE VALENCIA (ES) | 2019-03-12 | — | — | US | claimed |
| EP-3217985-B1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | UNIV VALENCIA (ES) | 2018-09-12 | — | — | EP | claimed |
| EP-3217984-B1 | CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2 | UNIV VALENCIA (ES) | 2018-09-12 | — | — | EP | claimed |
| US-20170312285-A1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | SELABTEC SCIENCES, SL (ES) | 2017-11-02 | — | — | US | claimed |
| EP-3020403-A1 | Compounds for the treatment of myotonic dystrophy | Universitat de Valéncia (ES) | 2016-05-18 | — | — | EP | claimed |
| EP-3020404-A1 | Caffeine for the treatment of myotonic dystrophy type 1 and type 2 | Universitat de Valéncia (ES) | 2016-05-18 | — | — | EP | claimed |
| US-20050148067-A1 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2005-07-07 | — | — | US | claimed |
| US-6855817-B2 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2005-02-15 | — | — | US | claimed |
| EP-1305328-A2 | MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES | Lyles, Mark B. (US) | 2003-05-02 | — | — | EP | claimed |
| US-20020103350-A1 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2002-08-01 | — | — | US | claimed |
| WO-2002008237-A2 | MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES | LYLES MARK B (US) | 2002-01-31 | — | — | WO | claimed |
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-01-18 | — | — | US | disclosed |
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-09-26 | — | — | US | disclosed |
| US-10226467-B2 | Compounds for the treatment of myotonic dystrophy | UNIVERSITAT DE VALENCIA (ES) | 2019-03-12 | — | — | US | disclosed |
| EP-3217985-B1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | UNIV VALENCIA (ES) | 2018-09-12 | — | — | EP | disclosed |
| US-20050148067-A1 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2005-07-07 | — | — | US | disclosed |
| US-6855817-B2 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2005-02-15 | — | — | US | disclosed |
| EP-1305328-A2 | MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES | Lyles, Mark B. (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020103350-A1 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2002-08-01 | — | — | US | disclosed |
| WO-2002008237-A2 | MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES | LYLES MARK B (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | BET1, BRD4, BRD3 | PDE4A 1873/4885PDE4B 1806/4885PDE4C 2442/4885 |
| US-20170312285-A1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | SMN1; SMN2, CPT1B, MTPN | PDE4A 826/4885PDE4B 580/4885PDE4C 1007/4885 |
| US-10226467-B2 | Compounds for the treatment of myotonic dystrophy | SMN1; SMN2, CPT1B, MTPN | PDE4A 826/4885PDE4B 580/4885PDE4C 1007/4885 |
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | BET1, BRD4, BRD3 | PDE4A 1873/4885PDE4B 1806/4885PDE4C 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.